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A 65-year-old woman diagnosed with a nodular melanoma on the
right shoulder had a PET/CT scan 13 months later demonstrating a
FDG-avid mass in the left masseter muscle, which was asymptom-
atic and not clinically evident. Pathologic analysis conﬁrmed
metastasis of melanoma. Further subcutaneous, intramuscular and
bone metastases developed and the patient was treated with sur-
geryand immunotherapy. The patient is in complete-remissionwith
no evidentmetastases seen on PET/CT 2.5 years after treatmentwith
adoptive cell therapy using tumor-inﬁltrating lymphocytes (TIL
therapy). Asymptomatic skeletal muscle metastases identiﬁed with
PET/CTcan have therapeutic and prognostic implications and a PET/
CT scan should be performed as a true whole-body scan.
© 2016 The Author(s). Published by Elsevier Ltd on behalf of British
Association of Plastic, Reconstructive and Aesthetic Surgeons. This
is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).Case report
A 65-year-old woman diagnosed in 2011 with a thick nodular melanoma on the right shoulder was
treated with wide local excision and sentinel lymph node biopsy (negative). At a routine follow up visitup).
ier Ltd on behalf of British Association of Plastic, Reconstructive and Aesthetic
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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further. There were no abnormal ﬁndings on clinical examination. A limited whole-body scan (LWB)
FDG PET/CT demonstrated a FDG-avid mass in the left masseter muscle (Figure 1). The corresponding
CT showed no abnormal ﬁndings. The lesion was not palpable. The patient underwent surgery and
histopathology conﬁrmed metastasis.
The patient was without symptoms, but a routine LWB PET/CT ﬁve months later showed a soft
tissue tumor in close proximity of the left sciatic nerve (Figure 2). Furthermore, the patient developed
a swollen red right ankle and magnetic resonance imaging (MRI) scan hereof showed a lesion in the
distal end of the ﬁbula suspicious of metastasis. Biopsies conﬁrmed metastatic lesions in both sites.
An extended whole-body (TWB) PET/CT scan in February 2013 showed progression of disease with
additional multiple subcutaneous metastases, and an osteolytic lesion in the sternum. Immuno-
therapy with interferon alfa-2b, pegylated (PEG-Intron) and interleukin (IL)-2 and later ipilimumab
were given.
A PET/CT thirteen months after immunotherapy was started demonstrated progression with mul-
tiple new cutaneous metastases (Figure 3). Treatment with adoptive cell therapy using tumor-
inﬁltrating lymphocytes (TIL therapy) was started.1 This personalized immunotherapy is based on
preconditioning chemotherapy followed by infusion of autologous tumor-inﬁltrating lymphocytes
(TIL) and T cell growth factor interleukin-2 (IL-2).1,2 The patient had a cutaneous metastasis excised
from which TILs were isolated, cultured, expanded and concentrated for treatment. Following pre-
conditioning lymphodepleting chemotherapy with cyclophosphamide and ﬂudarabine a single treat-
ment with infusion of TIL followed by IL-2 infusion was given. An evaluation PET/CT scan 4 months
after TIL therapy showed regression of the disease.Figure 1. A limited whole-body scan (LWB) FDG PET/CT demonstrated a FDG-avid mass in the left masseter muscle. Histopathology
conﬁrmed metastatic melanoma lesion.
Figure 2. Routine LWB PET/CT ﬁve months after surgical treatment of an isolated asymptomatic masseter muscle metastasis showed
a soft tissue tumor in close proximity of the left sciatic nerve.
Figure 3. PET/CT 13 months after immunotherapy was started demonstrated progression with multiple new cutaneous metastases.
Figure 4. PET/CT 24 months after adoptive cell therapy using tumor-inﬁltrating lymphocytes TIL therapy was started showed
complete-remission.
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well and is reviewed every six months with PET/CT with the latest PET/CT 2.5 years after TIL therapy
still showing complete-remission.
Discussion
Our case demonstrates isolated intramuscular metastases as the ﬁrst sign of metastatic disease in a
patient with known melanoma. In a study by Surov et al. skeletal muscle metastases in patients with
metastatic cancer were diagnosed incidentally in the majority (76.3%) of patients during routine
staging CT examinations.3 Among patients with metastatic melanoma, skeletal muscle metastases
were prevalent in 3.6%.3 The increased use of PET/CT allows the detection of skeletal muscle metastases
that would previously have remained undetected.4 PET/CT is superior for the detection of distant
metastases in both the staging and surveillance of melanoma patients.5 Nguyen et al. showed that a
signiﬁcant percentage of soft tissue metastases (46%) occurred outside the limited whole-body ﬁeld of
view.6 Similarly, the LWB PET/CTof our patient did not diagnose the bonemetastasis in the distal end of
the ﬁbula. A truewhole-body PET/CT does allow for amore accurate staging, restagingwith therapeutic
and prognostic implications for the patients.6,7
Until recently, the one-year survival rate for stage IV patients with M1c disease was 33%.8 However,
a new era of systemic therapy has led to signiﬁcant improvements in overall survival suggesting that
some patients may be cured.9 Evidence exists that current therapeutic options for metastatic disease
are more effective if the disease is treated with a lower disease burden.10,11 Hence, melanoma me-
tastases must be diagnosed early in order to maximize the chances of patient survival.
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